All Oncology News

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the OVAL trial.

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates represent a promising development for this population.

Polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, induced a 27% reduction in relative risk for disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Integrating the lived experiences of patients with relapsed or refractory diffuse-large B-cell lymphoma into treatment-decision making should be a priority for practicing oncologists.

Pirtobrutinib demonstrated potent antitumor activity and a low incidence of adverse effects in patients with BTK-pretreated and -naïve mantle cell lymphoma.

Treatment with zanubrutinib maintained or improved response without an increase in acalabrutinib intolerance events in patients with previously treated B-cell malignancies.

Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.

The European Commission has approved fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received at least 1 anti–HER2-based regimen.

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

The clinical development of Vicineum for use as a potential therapeutic option in patients with high-risk, Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Pralsetinib has been approved in Hong Kong, China, for use in treatment-naïve and pretreated adult patients with RET fusion–positive, metastatic non–small cell lung cancer.

Edward Kim, MD, and Myron E. Schwartz, MD, discuss the background and findings of the RASER study, the role of radiation segmentectomy, and its potential to be combined with immunotherapy.

The Philippine FDA has granted approval to alpelisib in combination with fulvestrant for the treatment of patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

Genetic testing has afforded oncologists with the opportunity to identify patients who may have a higher risk of developing cancer and identify actionable mutations to allow patients to receive targeted therapy and have their long-term treatment plan mapped out at diagnosis.

The European Medicines Agency has validated the marketing authorization application for trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome Alexander Philipovskiy, MD, PhD, as a principal investigator at the Florida Cancer Specialists & Research Institute Drug Development Unit.

Peer-reviewed articles continue to challenge the recognition of progression-free survival as an acceptable primary end point in randomized cancer trials or insist on labeling this objectively measured outcome as nothing more than a potential surrogate for effects representing actual clinically meaningful results.

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.

The emergence of novel agents like trastuzumab deruxtecan and tucatinib in the HER2-positive breast cancer treatment paradigm have served to markedly improve outcomes for those with this disease, according to Mark Pegram, MD, who added that the future looks bright.

The FDA has granted an orphan drug designation to NT-I7 for the treatment of patients with glioblastoma multiforme.

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.

Analyzing nearly 500,000 single cells, researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are refining how to classify colorectal cancer and identify new targets to develop effective therapies.

Major pathological response and recurrence-free survival rates were improved in women vs men with melanoma who received BRAF/MEK inhibitor therapy in the neoadjuvant setting.

Undocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.